Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Junk food companies are starting to get nervous over how many Americans use GLP-1 medications to lose weight. Washington Post ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The holidays can be a difficult time for those with a history of eating disorders, and having someone comment on their body – ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality ...

I’m wondering if any studies explain this and what’s the best way to address it. Should I increase the dose further or switch ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...